SGLT2 Inhibitors in Heart Failure - What's the Difference?

The new Canadian Cardiovascular Society Heart Failure Guidelines have quadruple therapy for all patients with reduced ejection fraction. In the prior guideline, there was a tiered system of three drugs: beta blockers, ACE inhibitors or ARBs and mineralic corticoid antagonist or MRAs. But as time went on, we accumulated more evidence that perhaps we should be starting more of these evidence-based therapies at an earlier point in a heart failure patient's trajectory. And then came the huge breakthrough of the SGLT2 inhibitors. Recently, two landmark trials were published in the New England Journal of Medicine regarding the use of S GLT2 inhibitors in heart failure with youth structure fraction. There was D